FMP

FMP

Enter

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Overview

-

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • The consensus price target for Xeris Biopharma's stock has been on an upward trend, indicating analyst optimism.
  • Craig-Hallum has set a higher price target of $6.5 for Xeris Biopharma, suggesting potential for significant stock appreciation.
  • Xeris Biopharma reported a 25% increase in total product sales in the first quarter, driven by Gvoke and Recorlev.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company that focuses on developing therapies in endocrinology, neurology, and gastroenterology. The company markets products like Gvoke, Keveyis, and Recorlev, and is expanding its product pipeline using its proprietary XeriSol and XeriJect platforms. Xeris competes in a challenging market with other biopharmaceutical companies.

The consensus price target for Xeris Biopharma's stock has shown an upward trend over the past year. Last year, the average price target was $4, which increased to $5 last quarter and remained steady last month. This optimism among analysts may be due to the company's progress in its development programs and successful commercialization of its products.

Craig-Hallum has set a higher price target of $6.5 for Xeris Biopharma, as highlighted by Seeking Alpha. This suggests that some analysts see even more potential for the company's stock. Xeris is currently trading above the Buy Threshold of $2.76 and is nearing a breakout above the $3.25 resistance level, indicating strong market interest.

Xeris Biopharma's revenue growth is primarily driven by its products Gvoke and Recorlev. In the first quarter, the company reported a 25% increase in total product sales compared to the previous year. CEO Paul Edick attributes this growth to the strong performance of Recorlev and the increasing market share of Gvoke.

Despite not yet reporting a positive EPS, Xeris Biopharma's projected revenue growth indicates significant upside potential. However, the company faces risks such as intense competition and the potential need for additional funding. Investors should monitor news related to Xeris Biopharma's earnings reports and product developments, as these could impact the stock's target price and market performance.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep